Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Leber

Showing results (71-80 of 125) with videos related to

Pageof 13
Sort By:
Cancer Cell|September 12, 2018
Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML RecurrenceAllison L Boyd, Lili Aslostovar, Jennifer Reid, et al.
American Journal of Blood Research|May 16, 2013
Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensusJoseph M Brandwein, Michelle Geddes, Jeannine Kassis, et al.
Blood|May 13, 2009
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirinSarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, et al.
American Journal of Clinical Pathology|October 1, 2016
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn GroupLambert Busque, Anna Porwit, Radmila Day, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 5, 2015
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms GroupShireen Sirhan, Lambert Busque, Lynda Foltz, et al.
Transplantation and Cellular Therapy|November 15, 2024
Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDSMichael Radford, Alejandro Garcia-Horton, Rohail Badami, et al.
European Journal of Haematology|September 23, 2018
How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registryChristopher J Patriquin, Thomas Kiss, Stephen Caplan, et al.
The Journal of Experimental Medicine|September 3, 2014
Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCsAllison L Boyd, Clinton J V Campbell, Claudia I Hopkins, et al.
American Journal of Hematology|September 23, 2022
Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinionNatasha Szuber, Panagiota Toliopoulos, Lambert Busque, et al.
Leukemia & Lymphoma|January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyMichael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Pageof 13

Showing results (71-80 of 125) with videos related to

Sort By:
Pageof 13
Cancer Cell|September 12, 2018
Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML RecurrenceAllison L Boyd, Lili Aslostovar, Jennifer Reid, et al.
American Journal of Blood Research|May 16, 2013
Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensusJoseph M Brandwein, Michelle Geddes, Jeannine Kassis, et al.
Blood|May 13, 2009
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirinSarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, et al.
American Journal of Clinical Pathology|October 1, 2016
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn GroupLambert Busque, Anna Porwit, Radmila Day, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 5, 2015
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms GroupShireen Sirhan, Lambert Busque, Lynda Foltz, et al.
Transplantation and Cellular Therapy|November 15, 2024
Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDSMichael Radford, Alejandro Garcia-Horton, Rohail Badami, et al.
European Journal of Haematology|September 23, 2018
How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registryChristopher J Patriquin, Thomas Kiss, Stephen Caplan, et al.
The Journal of Experimental Medicine|September 3, 2014
Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCsAllison L Boyd, Clinton J V Campbell, Claudia I Hopkins, et al.
American Journal of Hematology|September 23, 2022
Perioperative management of myeloproliferative neoplasms: A pan-Canadian physician survey and international expert opinionNatasha Szuber, Panagiota Toliopoulos, Lambert Busque, et al.
Leukemia & Lymphoma|January 30, 2010
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group StudyMichael Crump, David Hedley, Suzanne Kamel-Reid, et al.
Pageof 13